CCL2 and stroke disorder: For example, in rodent stroke models, inhibition of MCP-1 using knockout mice or anti-MCP-1 gene therapy results in fewer activated microglia and astrocytes and significantly smaller infarcts [22,45], while overexpression of MCP-1 is associated with increased chemoattraction of immune cells and larger infarct volumes [46].